Abstract
Emergent cardiovascular surgeries involving cardiopulmonary bypass (CPB) frequently trigger systemic inflammatory response syndrome (SIRS), often leading to acute lung injury (ALI). This study investigates the efficacy of sivelestat, a neutrophil elastase inhibitor, in mitigating these complications. In a propensity-score matched retrospective analysis of 100 patients, sivelestat significantly reduced pneumonia rates, shortened mechanical ventilation duration, and lowered systemic inflammatory markers, although it did not significantly alter 30-day mortality.
Introduction
Cardiopulmonary bypass (CPB) is essential for many cardiovascular procedures but is known to induce a "cytokine storm" or SIRS. Neutrophils, activated during CPB, release neutrophil elastase, an enzyme that degrades lung tissue and increases capillary permeability. This process is a primary driver of postoperative ALI and ARDS. While sivelestat has shown benefits in elective surgeries, its role in high-risk emergent cardiovascular surgeries—where inflammation is typically more severe—remained a major clinical question.
Methods
Researchers at Nanjing Drum Tower Hospital conducted a retrospective case-control study of 665 patients undergoing emergency cardiovascular surgery between 2020 and 2022. To mitigate selection bias inherent in retrospective designs, propensity-score matching (PSM) was employed to create balanced cohorts.
The intervention group (n=50) received sivelestat (0.2 mg/kg/h for 3 days), while the control group (n=50) received standard care. Matching criteria included age, sex, BMI, heart function (LVEF), and surgery type to ensure statistical rigor.
Results
The administration of sivelestat led to significant improvements in several secondary clinical outcomes. Pneumonia rates decreased from 62% in the control group to 40% in the sivelestat group (P=0.03). Furthermore, the median duration of mechanical ventilation was reduced by over 48 hours (96 vs. 148 hours, P<0.01), and the median ICU stay was shortened from 9 to 7 days (P<0.01).
Inflammatory biomarkers, including IL-6, CRP, and procalcitonin, were significantly lower in the sivelestat group by the second and third postoperative days. Oxygenation indices also showed earlier improvement in treated patients, suggesting a direct protective effect on lung tissue.
Despite these clinical benefits, there was no statistically significant difference in the primary composite outcome, which included 30-day mortality (P=0.412), as shown in the survival analysis.
Discussion
Sivelestat appears to function by inhibiting the activity of neutrophil elastase rather than reducing the absolute number of neutrophils, thereby preserving basic immune function while preventing tissue damage. This lung-specific protection is particularly valuable in emergent cases where baseline inflammation is high.
Limitations of this study include its retrospective nature, single-center data, and a relatively small matched sample size, which may have limited the power to detect differences in mortality. Future multi-center randomized controlled trials are necessary to confirm these findings and potentially integrate sivelestat into standard protocols for emergent CPB patients.
Summary updated